CN1507882A - Medicine for treating lung cancer and preparing method thereof - Google Patents
Medicine for treating lung cancer and preparing method thereof Download PDFInfo
- Publication number
- CN1507882A CN1507882A CNA021387370A CN02138737A CN1507882A CN 1507882 A CN1507882 A CN 1507882A CN A021387370 A CNA021387370 A CN A021387370A CN 02138737 A CN02138737 A CN 02138737A CN 1507882 A CN1507882 A CN 1507882A
- Authority
- CN
- China
- Prior art keywords
- medicine
- radix
- treatment
- parts
- percolate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a Chinese medicine for curing cancer of lung and its preparation method. The main component of said oral Chinese medicine preparation includes 11 Chinese medicinal materials of astragalus root, glehnia root, ophiopogon tuber, gynostemma pentaphylla, cornus fruit, ligustrum fruit and others. Its preparation method mainly adopts seepage process to obtain liquid medicine.
Description
Technical field
The present invention relates to a kind of medicine and preparation technology thereof, especially a kind of medicine for the treatment of pulmonary carcinoma and preparation method thereof.
Background technology
Most means of treatment pulmonary carcinoma are to adopt chemotherapy at present, and the patient is very painful in therapeutic process.
Summary of the invention
The object of the present invention is to provide a kind of medicine for the treatment of pulmonary carcinoma and preparation method thereof, this prescription just patient is taken.
Technical scheme of the present invention is: a kind of medicine for the treatment of pulmonary carcinoma, its described material component is: (umber is a weight portion)
Radix Astragali 2.74-3.05 Radix Glehniae 2.74-3.05 0.93-1.03 Radix Ophiopogonis
Herb Gynostemmae Pentaphylli 0.93-1.03 Fructus Corni 0.93-1.03 Fructus Ligustri Lucidi (processed with wine) 0.93-1.03
Herba Epimedii 0.93-1.03 Herba Selaginellae Doederleinii 2.74-3.05 Semen Trigonellae (saline stir-fry) 0.93-1.03
Herba Salviae Chinensis 2.74-3.05 Rhizoma Paridis 1.38-1.55 Radix Asparagi 1.38-1.55
The preparation method of this medicine is: 1, coarse powder is cleaned, dries, is crushed to the raw material of choosing; 2, according to fluid extract and extractum item percolation down, as solvent coarse powder is flooded percolation after 24 hours with concentration is 55%, deal is 117-129 ethanol, percolation speed is 2-3ml/kg minute, the percolate that collection medical material amount is 82 parts; 3, add 927 parts of pure water at percolate, be lower than under the condition that 85 ℃ or vacuum is not less than 0.05Mp in temperature percolate is evaporated to 850 parts; 4, with the NaOH of concentration 20% pH value of percolate is adjusted into 5.5-6.5, filters to get filtrate; 5, in filtrate, add 200 parts of sucrose, 3 parts of sodium benzoate, stir evenly promptly.
The invention has the advantages that: this medicine is easy to the patient and takes, reduce the patient suffering, and this medicine is made as oral liquid formulation, corrected to a certain extent medicine bitterness, improved mouthfeel, patient is taken like a shot and take, the packing of this process using easy-open lid bottle, taking convenience also is suitable for industrial automation production simultaneously.
Carry out physicochemical property research according to each medical material among documents and materials report and the other side, the contained effective constituent that mainly contains of Fang Zhongshi two flavor medical materials mostly is water-soluble components, wherein there is the seven flavor medicine material to contain Saponin, contain compositions such as cupreol, alkaloid, flavone, saccharide, pigment in addition, wherein Radix Glehniae contain micro-volatile oil [4] so, and carry out pharmacological action and relatively screen, because of volatile oil content in the side few, and ethanol percolation also can propose part volatile oil, therefore, when design technology, do not consider singly to carry volatile oil.Carry out acute toxicity test in mice and clinical trial, the oral administration safety test, no animal dead does not show the overt toxicity reaction, the abdominal cavity LD of this handicraft yet
50Value be: the 28.16g/kg body weight, not only toxicity reduces, and the EC solid tumor is had certain curative effect.
Longhua, Shanghai hospital, traditional Chinese medical science oncotherapy center, the whole nation has been carried out 301 examples, 304 examples, 173 examples and 30 examples respectively for many years through breast inspection, CT examination and fiberoptic bronchoscopy, and, contrast clinical observation proof Jin Fukang with chemotherapy group and have following effect through the patient that cytology and pathological examination the turn out to be primary lung cancer random packet of being admitted to hospital.
1, prolongs patient's life cycle
After the treatment, Jin Fukang group: median survival interval average out to 427 days, chemotherapy group are 265 days, and 5 years survival rates of gold group are 24.22%, and chemotherapy group is 0, and Jin Fukang has absolute sense life cycle to prolonging patients with lung cancer.
Table one: rate from bottom to top behind multiple health of pulmonary carcinoma gold and the chemotherapeutic treatment
| Grouping | 1 year | 2 years | 3 years | 4 years | 5 years | Median survival interval |
| The Jin Fukang group | 60.94 | ?36.77 | ?31.86 | ?24.22 | 24.22 | 427 days |
| Chemotherapy group | 36.67 | ?26.79 | ?24.56 | ?16.37 | 0 | 265 days |
| II | 2.540 | ?1.189 | ?0.905 | ?1.153 | 4.07 | |
| ?P | ＜0.05 | ?＜0.05 | ?＜0.05 | ?＜0.05 | ＜0.01 |
2, alleviation and stable focus
After the treatment, Jin Fukang group coefficient of stabilization is 67.83%, and the meta stable phase is 6 months, and chemotherapy group is that 48.12% meta stable phase is 3 months, and two groups of significant differences illustrate that Jin Fukang is better than chemotherapy group in the curative effect of stablizing focus.
Table two: the syndrome integration changes
| The Jin Fukang group | Chemotherapy group | |
| Symptom | Effective percentage (%) | Effective percentage (%) |
| Cough | 87.5 | ?36 |
| Expectorant blood | 67.2 | ?27.2 |
| Out of breath | 58.6 | ?30 |
| Heating | 76.3 | ?44.4 |
| Inappetence | 75 | ?16 |
| Spiritlessness and weakness | 83.8 | ?36 |
| Dry mouth and throat | 61.84 | ?28.57 |
| Chest pain | 84.9 | ?45.83 |
| Vexed mistake eye | 58.2 | ?26.08 |
| Shortness of breath and palpitation | 72.09 | ?29.4 |
| Spontaneous sweating | 62.31 | ?18.75 |
| Emaciated physique | 38.54 | ?37.5 |
| Nausea and vomiting | 29.16 | ?0.0 |
3, improve patient's life quality
Table three: body weight change before and after the treatment
| Grouping | Increase (%) | Stable (%) | Alleviate (%) |
| The Jin Fukang group | 46.9 | ?21 | ?32.1 |
| Chemotherapy group | 16 | ?24 | ?60 |
Table four: health status (karnofkg scoring) before and after the treatment
| Grouping | Raise (%) | Stable (%) | Reduce (%) |
| The Jin Fukang group | 18.8 | ?64 | ?17.2 |
| Chemotherapy group | 8 | ?40 | ?52 |
4, adjust body's immunity
After the treatment of Jin Fukang group, patient's LAK cell, the NK cytoactive, the gland lymphocyte produces the ability of (IL-2), T lymhocyte transformation rate OKT3, OKT4 and OKT4/OKT.Ratio all than before the treatment remarkable rising being arranged, and serum sialic acid content is reduced, show that Jin Fukang has the immunologic function that improves pulmonary carcinoma person, the effect that especially improves the immunologically competent cell function.
Table five: the variation of T-lymphocyte transformation function before and after the treatment
| Project | ????n | Treatment preceding (CPM) (X ± sD) | Treatment back (CPM) (X ± sD) | ????t | ????p |
| The Jin Fukang group | 69 | ?3824±6666 | ?11486±6771 | ???2.4067 | ＜0.05 |
| The MOF group | 50 | ?12644±8460 | ?10663±6904 | ???0.9605 | ＞0.05 |
Table six: t lymphocyte subset group's variation before and after the treatment
Table seven: the variation of treatment back patients with lung cancer LAK cytoactive
| Project | n | Treatment preceding () (X ± SD) | Treatment back () (X ± SD) | ??t | ??P | |
| The Jin Fukang group | ??OKT3 | ??130 | ??33.37±3.31 | ??37.33±5.31 | ??3.7576 | ??0.01 |
| ??OKT4 | ??130 | ??35.75±4.30 | ??37.62±3.96 | ??4.2404 | ??＜0.01 | |
| ??OKT8 | ??130 | ??24.52±2.33 | ??24.53±2.60 | ??0.2277 | ??＞0.05 | |
| ??OKT4/OKT3 | ??130 | ??1.477±0.21 | ??1.541±0.20 | ??2.7010 | ??＜0.01 | |
| Chemotherapy group | ??OKT3 | ??46 | ??54.17±5.97 | ??53.616.53 | ??0.4256 | ??＞0.05 |
| ??OKT4 | ??46 | ??63.15±5.89 | ??33.05±6.59 | ??2.1638 | ??＜0.05 | |
| ??OKT8 | ??46 | ??23.41±3.39 | ??25.00±2.02 | ??2.8831 | ??＜0.01 | |
| ??OKT4/OKT3 | ??46 | ??1.549±0.296 | ??1.346±0.243 | ??3.0975 | ??＜0.01 | |
| Group | ??n | Before the treatment (X ± SD) | The treatment back (X ± SD) | ??t | ??P |
| The Jin Fukang group | ??22 | ??19.33±11.16 | ??29.99±19.7 | ??2.49 | ??0.0211 |
| The MOF group | ??8 | ??24.96±12.86 | ??23.96±8.7 | ??0.80 | ??0.7726 |
Table eight: the variation that treatment back peripheral blood from patients with lung cancer lymphocyte produces the IL-2 ability
| Group | ??n | Before the treatment (X ± SD) | The treatment back (X ± SD) | ??t | ??P |
| The Jin Fukang group | ??22 | ??14.70±16.24 | ??27.70±25.50 | ??2.0900 | ??0.0409 |
| The MOF group | ??8 | ??19.34±22.3 | ??23.31±17.25 | ??0.3765 | ??0.7177 |
Table nine: the variation of NK cytoactive before and after the treatment
| Project | ??n | Treatment preceding () (X ± SD) | Treatment back () (X ± SD) | ??t | ??P |
| The Jin Fukang group | ??150 | ??31.20±15.58 | ??38.50±17.17 | ??5.2007 | ??0.01 |
| The MOF group | ??64 | ??33.95±15.55 | ??34.47±15.42 | ??0.2130 | ??0.05 |
Table ten: the variation of serum sialic acid content before and after the treatment
| Project | ??n | Before the treatment (X ± sD) | The treatment back (X ± sD) | ??t | ??p |
| The Jin Fukang group | ??91 | ??0.0410±0.091 | ??0.409±0.111 | ??0.9053 | ??＞0.05 |
| The MOF group | ??71 | ??0.389±0.105 | ??0.409±0.131 | ??1.3773 | ??＞0.05 |
The specific embodiment
A kind of preparation method for the treatment of the medicine of pulmonary carcinoma, the steps include: 1, the 2.92 gram Radixs Astragali, 2.92 gram Radix Glehniaes, 0.98 gram Radix Ophiopogonis, 0.98 gram Herb Gynostemmae Pentaphylli, the 0.98 Keshan Fructus Evodiae, 0.98 gram Fructus Ligustri Lucidi (processed with wine), 0.98 gram Herba Epimedii, 2.92 gram Herba Selaginellae Doederleiniis, 0.98 gram Semen Trigonellae (saline stir-frys), 2.92 gram Herba Salviae Chinensiss, the 1.46th grammes per square metre buildings, 1.46 are restrained Radix Asparagis, coarse powder is cleaned, dries, is crushed to the raw material of choosing; 2, according to fluid extract and extractum item percolation down, being 55% ethanol with 20.5 gram concentration floods percolation after 24 hours as solvent with coarse powder, and percolation speed is 2-3ml/kg minute, the percolate that collection medical material amount is 82 parts; 3, add 927 parts of pure water at percolate, be lower than under the condition that 85 ℃ or vacuum is not less than 0.05Mp in temperature percolate is evaporated to 850 parts; 4, with the NaOH of concentration 20% pH value of percolate is adjusted into 5.5-6.5, filters to get filtrate; 5, in filtrate, add 200 parts of sucrose, 3 parts of sodium benzoate, stir evenly promptly.
Side's Chinese crude drug is except that Fructus Ligustri Lucidi, Semen Trigonellae, and all the other ten flavors are removed impurity by 90 editions requirements of Chinese Pharmacopoeia respectively, with water purification [1] cleaning, drying.Fructus Ligustri Lucidi is made wine Fructus Ligustri Lucidi [2] in accordance with the law.Semen Trigonellae is made salt in accordance with the law and is fried Semen Trigonellae [3], drying.
Claims (3)
1, a kind of medicine for the treatment of pulmonary carcinoma is characterized in that: its described material component is: (umber is a weight portion)
Radix Astragali 2.74-3.05 Radix Glehniae 2.74-3.05 0.93-1.03 Radix Ophiopogonis
Herb Gynostemmae Pentaphylli 0.9 3-1.03 Fructus Corni 0.9 3-1.03 Fructus Ligustri Lucidi (processed with wine) 0.93-1.03
Herba Epimedii 0.9 3-1.03 Herba Selaginellae Doederleinii 2.74-3.05 Semen Trigonellae (saline stir-fry) 0.93-1.03
Herba Salviae Chinensis 2.74-3.05 Rhizoma Paridis 1.38-1.55 Radix Asparagi 1.38-1.55
2, a kind of medicine for the treatment of pulmonary carcinoma according to claim 1, it is characterized in that: the preparation method of this medicine is:
1, coarse powder is cleaned, dries, is crushed to the raw material of choosing;
2, according to fluid extract and extractum item percolation down, as solvent coarse powder is flooded percolation after 24 hours with concentration is 55%, deal is 117-129 ethanol, percolation speed is 2-3ml/kg minute, the percolate that collection medical material amount is 82 parts;
3, add 927 parts of pure water at percolate, be lower than under the condition that 85 ℃ or vacuum is not less than 0.05Mp in temperature percolate is evaporated to 850 parts;
4, with the NaOH of concentration 20% pH value of percolate is adjusted into 5.5-6.5, filters to get filtrate;
5, in filtrate, add 200 parts of sucrose, 3 parts of sodium benzoate, stir evenly promptly;
3, a kind of medicine for the treatment of pulmonary carcinoma according to claim 1, it is characterized in that: its described material component is: (umber is a weight portion)
2.92 Radix Ophiopogonis 0.98 of the Radix Astragali 2.92 Radix Glehniaes
Herb Gynostemmae Pentaphylli 0.98 Fructus Corni, 0.98 Fructus Ligustri Lucidi (processed with wine) 0.98
Cypress 2.92 Semen Trigonellaes on the Herba Epimedii 0.98 (saline stir-fry) 0.98
Herba Salviae Chinensis 2.92 Rhizoma Paridis 1.46 Radix Asparagis 1.46
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02138737 CN1242751C (en) | 2002-06-27 | 2002-06-27 | Medicine for treating lung cancer and preparing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02138737 CN1242751C (en) | 2002-06-27 | 2002-06-27 | Medicine for treating lung cancer and preparing method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1507882A true CN1507882A (en) | 2004-06-30 |
| CN1242751C CN1242751C (en) | 2006-02-22 |
Family
ID=34231776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02138737 Expired - Fee Related CN1242751C (en) | 2002-06-27 | 2002-06-27 | Medicine for treating lung cancer and preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1242751C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005058337A1 (en) * | 2003-12-19 | 2005-06-30 | Jiangxi Yicun Pharmaceutical Co., Ltd | Pharmaceuticals of chinese traditional medicine of treating lung cancer and preparation method thereof |
| CN1323710C (en) * | 2005-09-27 | 2007-07-04 | 韩云超 | Lung cancer treating Chinese medicine |
| CN100348249C (en) * | 2006-03-03 | 2007-11-14 | 陕西新药技术开发中心 | Method for preparing medicine for treating malignancy disease and use thereof |
| CN103169779A (en) * | 2013-03-12 | 2013-06-26 | 翁捷 | Medicinal composition for treating lung cancer |
| CN107432906A (en) * | 2016-05-26 | 2017-12-05 | 上海中医药大学附属龙华医院 | Prevent and treat Chinese medicine composition of lung cancer and application thereof |
| CN108743796A (en) * | 2018-09-19 | 2018-11-06 | 上海中医药大学附属岳阳中西医结合医院 | A kind of Chinese medicine composition that treating lung cancer and its application |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12091222B2 (en) | 2019-05-24 | 2024-09-17 | Conopco Inc. | Cap system for a concentrated refill capsule |
-
2002
- 2002-06-27 CN CN 02138737 patent/CN1242751C/en not_active Expired - Fee Related
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005058337A1 (en) * | 2003-12-19 | 2005-06-30 | Jiangxi Yicun Pharmaceutical Co., Ltd | Pharmaceuticals of chinese traditional medicine of treating lung cancer and preparation method thereof |
| CN100478014C (en) * | 2003-12-19 | 2009-04-15 | 江西一村制药有限责任公司 | A Chinese medicinal preparation for treating lung cancer and its preparation method |
| CN1323710C (en) * | 2005-09-27 | 2007-07-04 | 韩云超 | Lung cancer treating Chinese medicine |
| CN100348249C (en) * | 2006-03-03 | 2007-11-14 | 陕西新药技术开发中心 | Method for preparing medicine for treating malignancy disease and use thereof |
| CN103169779A (en) * | 2013-03-12 | 2013-06-26 | 翁捷 | Medicinal composition for treating lung cancer |
| CN103169779B (en) * | 2013-03-12 | 2016-02-17 | 北京弘泰安康医药科技有限公司 | A kind of pharmaceutical composition for the treatment of pulmonary carcinoma |
| CN107432906A (en) * | 2016-05-26 | 2017-12-05 | 上海中医药大学附属龙华医院 | Prevent and treat Chinese medicine composition of lung cancer and application thereof |
| CN108743796A (en) * | 2018-09-19 | 2018-11-06 | 上海中医药大学附属岳阳中西医结合医院 | A kind of Chinese medicine composition that treating lung cancer and its application |
| CN108743796B (en) * | 2018-09-19 | 2021-03-23 | 上海中医药大学附属岳阳中西医结合医院 | Traditional Chinese medicine composition for treating lung cancer and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1242751C (en) | 2006-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103768534B (en) | A kind of Chinese medicine composition with antitumor activity | |
| CN1265715C (en) | Bitter gourd cold tea and its production method | |
| CN108530551B (en) | Preparation of fritillaria polysaccharide and application of fritillaria polysaccharide in preparation of antitumor drugs | |
| CN102271698A (en) | Pharmaceutical composition and use for preparing medicament thereof | |
| CN101904974B (en) | Chinese medicinal composition for treating malignant tumor diseases and preparation method thereof | |
| CN1242751C (en) | Medicine for treating lung cancer and preparing method thereof | |
| CN104857435B (en) | A kind of Traditional Chinese medicine compound composition with antitumor activity and its preparation method and application | |
| CN1682828A (en) | Yinhuang lung clearing capsule and its preparing method | |
| CN1054370A (en) | A kind of manufacture method of kidney-tonifying health-care medicament | |
| CN1864718A (en) | A polysaccharide composition for tumor aid treatment, its preparation and application | |
| CN1596970A (en) | Traditional Chinese medicament for treating woman subhealthy faligue syndrome and its preparation method | |
| CN101254263A (en) | Compound Japanese polygala oral liquid and method of preparing the same | |
| CN109602759A (en) | The purposes of kusamaki broad-leaved podocarpus seed and receptacle polysaccharide | |
| CN1057398A (en) | The preparation method of oral liquid of agastachis for restoring health | |
| CN113785948A (en) | Solid beverage capable of benefiting qi, promoting production of body fluid and relaxing bowel and preparation method thereof | |
| CN106581236A (en) | Medicinal composition for promoting gastric motility, and preparation method and application thereof | |
| CN104825784B (en) | A kind of Chinese medicine composition with anti-gastric cancer activity and its preparation method and application | |
| CN104825783A (en) | Traditional Chinese medicine composition with anti-tumor activity and preparation method and application of traditional Chinese medicine composition | |
| CN1237998C (en) | Effervescence tablet for treating children's cough and asthma and its preparation | |
| CN108619228B (en) | Pharmaceutical composition and preparation method and application thereof | |
| CN115869373B (en) | Oral liquid for strengthening children and promoting digestion and preparation method thereof | |
| CN1101559A (en) | Traditional Chinese medicine oral administration liquid for anti-cancer and its preparing method | |
| CN107158062B (en) | Tumor adjuvant therapy medicine and application thereof | |
| CN108186874B (en) | A Chinese medicinal composition for treating diabetes | |
| CN1927376A (en) | Small thorowax droplet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060222 Termination date: 20150627 |
|
| EXPY | Termination of patent right or utility model |